key: cord-0959988-pgfzb1n5
authors: Huber, Meret K.; Raichle, Claudia; Lingor, Paul; Synofzik, Matthis; Borgmann, Stefan; Erber, Johanna; Tometten, Lukas; Rimili, Wolfgang; Dolff, Sebastian; Wille, Kai; Knauss, Samuel; Piepel, Christiane; Lanznaster, Julia; Rieg, Siegbert; Prasser, Fabian; Pilgram, Lisa; Spottke, Annika; Klockgether, Thomas; Klein, Christine; Hopfner, Franziska; Höglinger, Günter U.
title: Outcomes of SARS‐CoV‐2 Infections in Patients With Neurodegenerative Diseases in the LEOSS Cohort
date: 2021-02-27
journal: Mov Disord
DOI: 10.1002/mds.28554
sha: 6a27a21db2522e525a7f6c0f0240abe88c4c23b7
doc_id: 959988
cord_uid: pgfzb1n5

nan

Using a systematic sampling strategy, we extracted 15 controls randomly from the study population for each PD patient (1:15) and 2 randomly selected controls for each dementia patient (1:2) . Any potentially confounding effects resulting from variability in age and sex were fully adjusted for by the matching procedure. To avoid bias, we handled patients and controls the same way according to standard epidemiological principles.

The overall SARS-CoV-2-associated mortality in the PD (32.5%) and dementia (32.1%) groups did not significantly differ from their respective control groups (28.7% and 26.5%).

Delirium occurred more frequently in dementia compared to PD and controls, but patient-reported parameters (eg, dry cough and dyspnoe) were less frequent in dementia compared to PD and controls. Interestingly, dementia patients remained in the ICU and were ventilated for a shorter time period than controls. The major SARS-CoV-2 outcome parameters (duration of inpatient stay, duration of ICU stay, and duration of ventilation; SARS-CoV-2-related mortality) were also not significantly different between PD patients, dementia patients, and controls. The age and gender distributions in our patient sample were not significantly different from previously published epidemiological cohort studies reporting the typical characteristics of German PD and dementia patients. [2] [3] [4] [5] This suggests that our sample was representative of the patients observed in the general population. Only the subgroup of female dementia patients had a higher mortality than their female controls (Table 1) .

Although prior studies have reported higher SARS-CoV-2-related mortality in patients with PD or dementia compared to patients without preexisting neurodegenerative diseases, 6,7 encouragingly, our comparably relatively large, well-controlled, standardized data set with prospective patient enrollment does not support the notion of an increased risk for a fatal course of SARS-CoV-2 in PD or dementia patients, when treated in tertiary referral centers. Further research is required to shed light on the impact of gender on the outcome of SARS-CoV-2 infections in dementia patients.

Approval for LEOSS was obtained by the applicable local ethics committees of all participating centers and registered at the German Clinical Trials Register (DRKS, number S000 21145). Adjusted for age and sex. Univariate statistical analyses were performed to determine the significance between the analyzed subgroups. Odds ratios with the corresponding confidence intervals were generated. Abbreviations: PD, Parkinson's disease patients; D, dementia; controls, SARS-CoV-2 patients without comorbidities, Parkinson's disease or dementia; ICU, intensive care unit; OR, odds ratio; CI, confidence interval; OR, NA*, due to the data structure, multiple ORs are generated for the respective categories. These ORs can be obtained on request.

Agaplesion Diaconia Hospial Rotenburg (David Heigener), Hospital Leverkusen

First results of the "lean European open survey on SARS-CoV-2-infected patients (LEOSS)

Prevalence, duration and severity of Parkinson's disease in Germany: a combined meta-analysis from literature data and outpatient samples

Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years

Eine Schätzung des Krankenbestandes und der jährlichen Neuerkrankungen in Deutschland

Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region

Coronavirus disease 2019 case fatality and Parkinson's disease

Manuscript preparation: A. Writing of the first draft

Annika Spottke, and Thomas Klockgether report no disclosure. Paul Lingor is supported by the NUM research network of the BMBF (B-FAST) and the Bavarian Staatsministerium für Wissenschaft und Kunst, and Lisa Pilgram is funded by the Willy Robert Pitzer Foundation

Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology

Acknowledgments: We express our deep gratitude to all study teams supporting the LEOSS study. The LEOSS study group contributed at least 

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.